Concepedia

Author

Jasleen K. Randhawa

The University of Texas MD Anderson Cancer Center

Also Known As

Jasleen K Randhawa, Jasleen K. Randhawa, Jasleen Randhawa, Robert F. Cornell, Robert Frank Cornell

35

Publications

414

Citations

10

H-Index

11

Concepts

All Affiliations

The University of Texas MD Anderson Cancer CenterPrincess Margaret Cancer CentrePresbyterian HospitalFred Hutch Cancer CenterOttawa Hospital
JK

About

Jasleen K. Randhawa is an author at The University of Texas MD Anderson Cancer Center specializing in oncology, hematology, and medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

86

2

Hematology

2

2

86

3

Health Sciences

1

1

13

4

Immunology

1

1

13

5

Pharmacology

1

1

73

Jasleen K. Randhawa

×

9

Publications

347

Citations

9

H-Index

YearCitations

Results of a Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients (Pts) with Activating FLT3 Mutations

Jasleen K. Randhawa, Hagop M. Kantarjian, Gautam Borthakur,

Blood

2014

112

Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study

Guillermo Garcia‐Manero, James McCloskey, Elizabeth A. Griffiths,

The Lancet Haematology

2023

73

Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant

Premal Lulla, Swati Naik, Spyridoula Vasileiou,

Blood

2020

63

An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes

May Daher, Juliana Elisa Hidalgo Lopez, Jasleen K. Randhawa,

American Journal of Hematology

2017

27

Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Michael R. Savona, James McCloskey, Elizabeth A. Griffiths,

Blood

2020

21

A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia

Iman Abou Dalle, Jörge E. Cortes, Pramod Pinnamaneni,

Acta Haematologica

2018

17

Final outcomes of escalated melphalan 280 mg/m2 with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival

Parameswaran Hari, Donna Reece, Jasleen K. Randhawa,

Bone Marrow Transplantation

2018

13

Prolonged Survival in Bi-Allelic <i>TP53</i>-Mutated (<i>TP53</i>mut) MDS Subjects Treated with Oral Decitabine/Cedazuridine in the Ascertain Trial (ASTX727-02)

Michael R. Savona, James McCloskey, Elizabeth A. Griffiths,

Blood

2022

11

Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain Study

Guillermo Garcia‐Manero, James McCloskey, Elizabeth A. Griffiths,

Blood

2021

10

Page 1